Business Context and Reporting Period
This Form 8-K was filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on December 16, 2019. The registrant is a Delaware corporation with its principal executive offices in Stamford, Connecticut. The filing serves as a Regulation FD disclosure regarding an update to the company's corporate presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial data disclosures rather than financial performance metrics.
Material Changes and Clinical Updates
The primary material event reported is the update of the company's corporate presentation to include top-line data from the Phase 2 clinical trial of Oral KORSUVA for chronic kidney disease-associated pruritus. Key findings disclosed include:
- Statistically significant differences between Oral KORSUVA and placebo in the percentage of Numeric Rating Scale complete responders at Week 12.
- Statistically significant differences in the percentage of patients scoring "much improved" or "very much improved" on the Patient Global Impression of Change at Week 12.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclaimer that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the correct registrant name is Cara Therapeutics, Inc., as the input metadata contained a discrepancy.
- Review Exhibit 99.1 (Presentation dated December 2019) for the full dataset regarding the Oral KORSUVA Phase 2 trial.
- Confirm the statistical significance details for Week 12 endpoints in the full presentation.
- Note that this 8-K does not contain updated financial statements or liquidity data.